Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY2018 Earnings Presentation
8 slides from Aurobindo Pharma's earnings presentation, Aug 9, 2017
Slide 1: Q1 FY17-18 Earnings Presentation
Q1 FY17-18 EARNINGS PRESENTATION 9th August 2017
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Consolidated Financial & Business Highlights – Q1FY18
Consolidated Financial & Business Highlights – Q1FY18 Key Financial Highlights • Revenue from operations at INR 3,678.7 crore • EBIDTA at INR 841.6 crore vs INR 889.0 crore in Q1FY17; EBITDA margin at 22.9%. • PAT after JV share, minority interest at INR 518.5 crore • Basic & Diluted EPS is INR 8.85
Slide 4: US Filings Snapshot
US Filings Snapshot Addressable Cumulative ANDA Filings and Approvals Therapy ANDAs Market Size (US$ Bn) Anti Diabetic 13 5.3 ARV 41 8.4 CNS 82 25.2 Controlled Substances 16 2.2 CVS 70 26.3 Gastroenterological 28 4.9 Ophthalmics 11 0.6 Others 134 15.1 Penem 4 0.5 Respiratory 10 0.6 Oncology 3 0.9 SS
Slide 5: Consolidated Financial Performance – Q1FY18 YoY
Consolidated Financial Performance – Q1FY18 YoY Q1 Q1 % Value INR Cr Revenue from Operations - Breakup FY18 FY17 Chg Value in INR CR Q1FY18 Q1FY17 % Chg Formulations 3,051.0 3,032.1 0.6 USA 1,694.9 1,703.9 -0.5 API 625.0 734.5 -14.9 EU 917.6 831.2 10.4 Formulations % of sales 83.0% 80.5% Growth mark
Slide 6: Consolidated Financial Performance – Q1FY18 QoQ
Consolidated Financial Performance – Q1FY18 QoQ Q1 Q4 % Revenue from operations - Breakup Value INR Cr FY18 FY17 Chg Value in INR CR Q1FY18 Q4FY17 % Chg Formulations 3,051.0 2,879.4 6.0 USA 1,694.9 1,643.2 3.1 API 625.0 762.8 -18.1 EU 917.6 777.2 18.1 Growth markets 193.9 197.1 -1.6 Formulations % o
Slide 7: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-15 Mar-16 Mar-17 Jun-17 Closing Rate1 US$ = 62.50 66.255 64.85 64.58 INR Fx Loan restated in 4,312.3 4,956.7 3,121.5 4,402.2 690 748 481 682 INR Rupee Loan 37.3 46.9 244.8 57.4 Sales Tax Deferment 54.9 41.9 0.0 0.0 Gross Debt 4,404.5 5,045.6 3,366.
Slide 8: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register